Emergent Biosolutions (NYSE:EBS) versus Collegium Pharmaceutical (COLL) Critical Contrast

Collegium Pharmaceutical (NASDAQ: COLL) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Institutional & Insider Ownership

84.0% of Collegium Pharmaceutical shares are owned by institutional investors. Comparatively, 86.0% of Emergent Biosolutions shares are owned by institutional investors. 25.8% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 16.5% of Emergent Biosolutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Collegium Pharmaceutical and Emergent Biosolutions’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Collegium Pharmaceutical $1.71 million 269.62 -$94.17 million ($2.98) -4.75
Emergent Biosolutions $488.78 million 3.43 $51.77 million $1.69 23.93

Emergent Biosolutions has higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Collegium Pharmaceutical has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500. Comparatively, Emergent Biosolutions has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.


This table compares Collegium Pharmaceutical and Emergent Biosolutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical -447.83% -77.11% -61.94%
Emergent Biosolutions 15.60% 15.20% 9.67%

Analyst Recommendations

This is a summary of current ratings and target prices for Collegium Pharmaceutical and Emergent Biosolutions, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical 0 0 5 0 3.00
Emergent Biosolutions 0 1 2 0 2.67

Collegium Pharmaceutical currently has a consensus target price of $20.00, suggesting a potential upside of 41.24%. Emergent Biosolutions has a consensus target price of $45.00, suggesting a potential upside of 11.28%. Given Collegium Pharmaceutical’s stronger consensus rating and higher probable upside, equities analysts clearly believe Collegium Pharmaceutical is more favorable than Emergent Biosolutions.


Emergent Biosolutions beats Collegium Pharmaceutical on 8 of the 13 factors compared between the two stocks.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply